Gonadotropin-Releasing Hormone Analogue Treatment: Differentiating Effects on Body Mass Index in Normal-Weight, Overweight, and Obese Girls

Introduction : Weight gain and BMI changes are concerns while treating central precocious puberty (CPP) with gonadotropin-releasing hormone agonist (GnRHa). This study investigates BMI changes with GnRHa treatment in idiopathic CPP girls of normal, overweight, and obese weight. Method : This study collected data from 188 girls with idiopathic CPP who received GnRHa therapy. BMI changes were analyzed during the treatment period, with participants stratified based on their baseline BMI status: normal weight (BMI < 1 SDS), overweight (BMI ≥ 1 SDS), and obese (BMI ≥ 2 SDS). Results : Obesity and overweight were prevalent, observed in 24.5% and 14.9% of the cases, respectively. The BMI-SDS of the normal-weight group increased significantly during the treatment period at the beginning of treatment, 12-months after treatment, and the end of treatment (0.01 ± 0.7, 0.23 ± 0.9, and 0.37 ± 1.0, P < 0.05). However, no significant changes in BMI-SDS were noted in the overweight and obese groups during the treatment period. Conclusion : The findings of our study indicate that the variations in BMI alterations observed in our CPP patients imply that the impact of GnRHa treatment-induced delayed puberty on linear growth may differ based on the initial body composition.